Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity

被引:58
|
作者
Ganta, Krishna Kumar [1 ]
Mandal, Anirban [1 ]
Chaubey, Binay [1 ,2 ,3 ]
机构
[1] Univ Calcutta, Dept Bot, Ctr Adv Study, Funct Genom Lab, 35 Ballygunge Circular Rd, Kolkata 700019, India
[2] Univ Gdansk, Intercollegiate Fac Biotechnol, Dept Recombinant Vaccines, Kladki 24, PL-80822 Gdansk, Poland
[3] Med Univ Gdansk, Kladki 24, PL-80822 Gdansk, Poland
关键词
Apoptosis; Cytotoxicity; Efavirenz; Mitochondrial membrane potential; HIV-INFECTED PATIENTS; CYTOCHROME-C RELEASE; CHRONIC HEPATITIS-C; ANTIRETROVIRAL THERAPIES; PLASMA-CONCENTRATIONS; TARGETING DRUGS; CELL-DEATH; APOPTOSIS; EXPRESSION; TOXICITY;
D O I
10.1007/s10565-016-9362-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and an active constituent of the highly active antiretroviral therapy regime. It has significantly contributed in control and management of human immunodeficiency virus propagation. However, EFV administration has also led to severe adverse effects, several reports highlighted the role of EFV in mitochondrial dysfunction and toxicity but the molecular mechanism has been poorly understood. In present study, human hepatoma cells Huh 7.5 were treated with clinically relevant concentrations of EFV and parameters like cytotoxicity, mitochondrial transmembrane potential, mitochondrial morphology, cytochrome c release, mitochondria-mediated apoptosis, mtDNA and mtRNA levels and EFV distribution into mitochondrial compartment were evaluated to understand sequence of events leading to cell death in EFV-treated cells. EFV at its clinically relevant concentration was significantly toxic after 48 and 72 h of treatments. EFV-mediated toxicity is initiated with the permeabilization of mitochondrial outer membrane and change in mitochondrial membrane potential (Delta psi m) which triggers a series of events like cytochrome c release, alteration in mitochondrial morphology and mitochondria-mediated apoptosis. Total mitochondrial content is reduced after 48 h of EFV treatment at IC50 concentration which is also reflected in reduced mitochondrial DNA and RNA levels. After detecting EFV in mitochondrial compartment after 12 h of incubation with EFV, we hypothesize that EFV being a lipophilic molecule is internalized into the mitochondrial compartment causing depolarization of Delta psi m which subsequently leads to a cascade of events causing cell death.
引用
收藏
页码:69 / 82
页数:14
相关论文
共 50 条
  • [11] The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations
    Wang, J.
    Liang, H.
    Bacheler, L.
    Wu, H.
    Deriziotis, K.
    Demeter, L. M.
    Dykes, C.
    VIROLOGY, 2010, 402 (02) : 228 - 237
  • [12] Synthesis of Some Novel Non-Nucleoside Reverse Transcriptase Inhibitor
    Bapna, Mayank
    Nema, R. K.
    ASIAN JOURNAL OF CHEMISTRY, 2009, 21 (02) : 1244 - 1248
  • [13] HIV-1 non-nucleoside reverse transcriptase inhibitor
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1998, 3 (08) : 387 - 387
  • [14] Convenient route to efavirenz analogues as potential non-nucleoside HIV-1 reverse transcriptase inhibitors
    Hamed, AA
    ZEITSCHRIFT FUR NATURFORSCHUNG SECTION B-A JOURNAL OF CHEMICAL SCIENCES, 2004, 59 (05): : 589 - 596
  • [15] The Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz-induces an inflammatory response in hepatic cells controlled by autophagy
    Blas-Garcia, Ana
    Alegre, Fernando
    Polo, Miriam
    Ortiz-Masia, Dolores
    Funes, Haryes A.
    Marti-Rodrigo, Alberto
    Apostolova, Nadezda
    Esplugues, Juan V.
    HEPATOLOGY, 2014, 60 : 712A - 712A
  • [16] HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation In Vitro and In Vivo
    Jin, Jingji
    Grimmig, Bethany
    Izzo, James
    Brown, Lecia A. M.
    Hudson, Charles
    Smith, Adam J.
    Tan, Jun
    Bickford, Paula C.
    Giunta, Brian
    CELL TRANSPLANTATION, 2016, 25 (11) : 1967 - 1977
  • [17] Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells
    Jamaluddin, Md Saha
    Lin, Peter H.
    Yao, Qizhi
    Chen, Changyi
    ATHEROSCLEROSIS, 2010, 208 (01) : 104 - 111
  • [18] Additive tumor toxic Effects by the Combination of the non-nucleoside Reverse Transcriptase-inhibitor Efavirenz with ionizing Radiation
    Koerber, V
    Distel, L.
    Schwegler, M.
    Harrer, T.
    Fietkau, R.
    Hecht, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 87 - 87
  • [19] CHARACTERIZATION OF THE BIOTRANSFORMATION OF THE HIV NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR RILPIVIRINE
    Lade, Julie M.
    Bumpus, Namandje N.
    DRUG METABOLISM REVIEWS, 2014, 45 : 186 - 187
  • [20] Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors
    Rivero, Antonio
    Mira, Jose A.
    Pineda, Juan A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (03) : 342 - 346